---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040572"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:51:55.835696+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q3 revenue $16M (record), net loss narrows to $1.1M, Adj. EBITDA positive $0.3M

## Summary
- Q3 net revenue $16.0M, up 23% YoY; net loss $1.1M vs $1.5M loss a year ago.
- Adjusted EBITDA positive $0.3M vs negative $1.6M in Q3 2022.
- Acquired certain collagen assets (CellerateRX, HYCOL) in August, eliminating future royalties.
- First sales of ALLOCYTE Plus and BIASURGE completed post-quarter; supply issues for ALLOCYTE resolved.
- Twelve new sales reps hired in 9M 2023; products sold in over 1,000 facilities across 32 states.

## SEC filing metadata
- accession: 0001493152-23-040572
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315223040572/0001493152-23-040572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315223040572/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040572
- JSON: https://secwatch.observer/filing/0001493152-23-040572.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040572.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the quarter ended September 30, 2023 results: revenue $16.0 million, net income net loss of $1.1 million.
  - Period: the quarter ended September 30, 2023
  - Revenue: $16.0 million
  - Net income: net loss of $1.1 million
  - Result: reported results
  source text: that can improve outcomes while reducing healthcare expenditures.” Third Quarter 2023 Strategic and Operational Highlights (Unaudited) ● The Company generated net revenue of $16.0 million for the three months ended September 30, 2023, an eighth consecutive record sales quarter. ● The Company’s loss before income taxes for the three months ended September 30,
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315223040572/0001493152-23-040572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.